0GO.F N4 PHARMA PLC -004

Healthcare Pharmaceuticals Frankfurt Exchange
0.0070 EUR
Close of Nov 11, 2026
0.0005 0.0265
Market cap
EUR 12.4M
P/E
-
P/B
4.22x
ROE
-112.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 0GO.F undervalued?

Graham number

The Graham number of N4 PHARMA PLC -004 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

N4 PHARMA PLC -004 fundamental analysis

No fundamental analysis for N4 PHARMA PLC -004 yet.

N4 PHARMA PLC -004 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About N4 PHARMA PLC -004

Thalia Therapeutics Plc, a biotechnology company, develops and delivers RNA-based therapeutics and technologies in oncology and cardiovascular disease in the United Kingdom. The company develops nanoparticle silica delivery systems to enhance the cellular delivery and potency of cancer treatments and vaccines. It also develops Nuvec, a pipeline of RNA therapeutics; and Liptide, a platform to deliver a proprietary siRNA sequence to silence a fibrotic gene. The company also en…

Full company profile